Venus Remedies Secures Indonesian Approval for Anticoagulant Enoxaparin

Venus Remedies Limited has announced that it has received market authorization for its anticoagulant drug Enoxaparin from Indonesia's regulatory authorities. This approval marks a significant milestone in the company's global expansion strategy, particularly in the thrombosis treatment market.

Enoxaparin, a low molecular weight heparin, is widely used to prevent and treat deep vein thrombosis and pulmonary embolism. It is also recommended for COVID-19 patients with elevated D-dimer levels or high risk of thrombosis.

This authorization aligns with Venus Remedies' recent string of approvals in multiple countries, including Morocco, the Philippines, and Saudi Arabia. The company continues to strengthen its presence in emerging markets, offering affordable and accessible treatments across various therapeutic areas.

Venus Remedies expects this approval to contribute significantly to its revenue growth in the coming quarters, as Indonesia represents a large and growing pharmaceutical market in Southeast Asia.

Source: Venus Remedies Limited